Orexigen Therapeutics (OREX) Misses Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to Orexigen Therapeutics (OREX) Misses Q4 EPS by 4c

Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2015

February 26, 2016 7:00 AM EST

SAN DIEGO, Feb. 26, 2016 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the fourth quarter and year ended December 31, 2015.

"Since the introduction of Contrave® to the United States market in October 2014, Takeda field representatives have engaged approximately 100,000 health care providers in nearly 1.1 million product discussions. 55,000 practitioners have written more than 765,000 prescriptions of Contrave. Levels of aided and unaided awareness are now high among HCPs," said Michael Narachi, CEO of Orexigen. "With this strong early effort, Contrave has quickly been established as the most... More